Advertisement


Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial (Italian Language Version)

2016 ASCO Annual Meeting

Advertisement

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses in Italian results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). 

 To see the English language version of this video, please click here.



Related Videos

Gynecologic Cancers

Eric Roeland, MD, and Linda Van Le, MD, on Gynecologic Cancers: Managing Menopausal Symptoms in Survivors

Eric Roeland, MD, of the University of California, San Diego, and Linda Van Le, MD, of the University of North Carolina discuss ways to manage symptoms that affect up to 80% of postmenopausal women, diminishing their quality of life.

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.

Multiple Myeloma

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial (Italian Language Version)

Antonio Palumbo, MD, of the University of Torino, discusses in Italian this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4). 

 To see the English language version of this video, please click here.

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Fabrice Denis, MD, PhD, on Lung Cancer: Improving Survival With an App

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discuss findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006). To see Dr. Denis discuss this study in French, click here.

  To see the French language version of this discussion, click here.

Issues in Oncology

Maria Clemence Schwaederle, PharmD, on Precision Medicine: Its Impact in Refractory Malignancies

Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).

Advertisement

Advertisement




Advertisement